Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Paula Chaves Mari, Reema Gulati & Philip Fragassi. (2021) Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges. Adolescent Health, Medicine and Therapeutics 12, pages 45-53.
Read now
Read now
Ying Wei, Jian Yang, Meena Kishore Sakharkar, Xia Wang, Qin Liu, Jiang Du & Jing-Jie Zhang. (2020) Evaluating the inhibitory effect of eight compounds from Daphne papyracea against the NS3/4A protease of hepatitis C virus. Natural Product Research 34:11, pages 1607-1610.
Read now
Read now
Nobuhisa Akamatsu, Yasuhiko Sugawara & Norihiro Kokudo. (2015) Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. Expert Review of Anti-infective Therapy 13:11, pages 1307-1317.
Read now
Read now
Syed-Mohammed Jafri & Stuart C. Gordon. (2015) The safety of daclatasvir for the treatment of hepatitis C. Expert Opinion on Drug Safety 14:11, pages 1787-1797.
Read now
Read now
Sandrine Cure, Ines Guerra, Calogero Cammà, Antonio Craxì & Giampiero Carosi. (2015) Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. Journal of Medical Economics 18:9, pages 678-690.
Read now
Read now
Ashley Arezou Minaei & Kris V Kowdley. (2015) ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opinion on Pharmacotherapy 16:6, pages 929-937.
Read now
Read now
James J Kohler, James H Nettles, Franck Amblard, Selwyn J Hurwitz, Leda Bassit, Richard A Stanton, Maryam Ehteshami & Raymond F Schinazi. (2014) Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infection and Drug Resistance 7, pages 41-56.
Read now
Read now
Ezequiel Ridruejo. (2014) Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Expert Opinion on Drug Safety 13:3, pages 307-319.
Read now
Read now
Articles from other publishers (56)
Howard Thom, Joy Leahy & Jeroen P. Jansen. (2022) Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias. Medical Decision Making 42:7, pages 906-922.
Crossref
Crossref
Muhammad Arba, Setyanto Tri Wahyudi, Muhammad Sulaiman Zubair, Dylan Brunt, Mursalin Singh & Chun Wu. (2022) Binding of GS-461203 and Its Halogen Derivatives to HCV Genotype 2a RNA Polymerase Drug Resistance Mutants. Scientia Pharmaceutica 90:2, pages 26.
Crossref
Crossref
Javier García-Cárceles, Elena Caballero, Carmen Gil & Ana Martínez. (2021) Kinase Inhibitors as Underexplored Antiviral Agents. Journal of Medicinal Chemistry 65:2, pages 935-954.
Crossref
Crossref
Hyejin Lee, Dnyandev B. Jarhad, Ahrim Lee, Choongho Lee & Lak Shin Jeong. (2021) 4′‐Selenonucleosides: Regio‐ and Stereoselective Synthesis of Novel Ribavirin and Acadesine Analogs as Anti‐Hepatitis C Virus (HCV) Agents. Asian Journal of Organic Chemistry 10:11, pages 2993-2999.
Crossref
Crossref
Sarah Y. Neshat, Victor M. Quiroz, Yuanjia Wang, Sebastian Tamayo & Joshua C. Doloff. (2021) Liver Disease: Induction, Progression, Immunological Mechanisms, and Therapeutic Interventions. International Journal of Molecular Sciences 22:13, pages 6777.
Crossref
Crossref
Denis Ouzan, Dominique Larrey, Dominique Guyader, André-Jean Remy, Ghassan Riachi, Fréderic Heluwaert, Régine Truchi, Jean-Marc Combis, François Bailly, Isabelle Rosa, Christophe Hézode, Denise Glorian-Petraud, Olivier Libert, Heribert Ramroth, Tarik Asselah, Gérard Thiefin, Dominique Roulot, Bruno Roche, Vincent Leroy, Jérôme Dumortier, Dominique Thabut & Stanislas Pol. (2020) Evolution of Hepatitis C Virus Treatment During the Era of Sofosbuvir-Based Therapies: A Real-World Experience in France. Digestive Diseases and Sciences 66:3, pages 881-898.
Crossref
Crossref
Caroline O’Keefe-Markman, Kristina Dawn Lea, Christopher McCabe, Elaine Hyshka & Tania Bubela. (2020) Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment. BMC Public Health 20:1.
Crossref
Crossref
Mojtaba Tahmoorespur, Marjan Azghandi, Ali Javadmanesh, Zahra Meshkat & Mohammad Hadi Sekhavati. (2019) A Novel Chimeric Anti-HCV Peptide Derived from Camel Lactoferrin and Molecular Level Insight on Its Interaction with E2. International Journal of Peptide Research and Therapeutics 26:3, pages 1593-1605.
Crossref
Crossref
Elnaz Agi, Samira Hojjatipour, Ali Namvar & Azam Bolhassani. (2020) Impact of Blood Transfusion on the Prevalence of HHpgV-1, HPgV-1, and B19V Among Iranian HCV-infected Patients With Hemophilia. Journal of Pediatric Hematology/Oncology 42:4, pages e213-e218.
Crossref
Crossref
Elnaz Agi, Saber Asghari, Ali Namvar, Niloofar Khairkhah, Niloofar Naderi, Ali Anvar, Alireza Azizi Saraji & Azam Bolhassani. (2020) Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents. Journal of Medical Microbiology and Infectious Diseases 8:1, pages 1-6.
Crossref
Crossref
Claudia Colomba, Laura Saporito, Paola Di Carlo, Manlio Tolomeo, Adriana Cervo, Alberto Firenze, Marcello Trizzino & Antonio Cascio. (2019) Direct-acting antivirals and visceral leishmaniasis: a case report. BMC Infectious Diseases 19:1.
Crossref
Crossref
Marcello Persico, Andrea Aglitti, Michele Milella, Carmine Coppola, Vincenzo Messina, Ernesto Claar, Ivan Gentile, Fernando Sogari, Paola Pierri, Lorenzo A. Surace, Filomena Morisco, Paolo Tundo, Giuseppina Brancaccio, Gaetano Serviddio, Pietro Gatti, Antonio P. Termite, Giovan G. Di Costanzo, Benedetto Caroleo, Raffaele Cozzolongo, Nicola Coppola, Annamaria Longo, Luca Fontanella, Alessandro Federico, Valerio Rosato, Irene Terrenato & Mario Masarone. (2019) Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. Liver International 39:10, pages 1852-1859.
Crossref
Crossref
Niloofar Naderi, Ghazal Masoudi, Bita Behnava, Seyed Moayed Alavian, Soyar Sari, Ali Anvar, Alireza Azizi Saraji, Ali Namvar & Azam Bolhassani. (2018) Detection of Occult Hepatitis B Virus Among Iranian HCV-Infected Patients with Hemophilia Treated with Direct-Acting Antiviral Agents. Hepatitis Monthly In Press:In Press.
Crossref
Crossref
Takuya Kuwashiro, Shinji Iwane, Xia Jinghe, Sachiko Matsuhashi, Yuichiro Eguchi, Keizo Anzai, Kazuma Fujimoto, Toshihiko Mizuta, Naoya Sakamoto, Masanori Ikeda, Nobuyuki Kato & Iwata Ozaki. (2018) Regulation of interferon signaling and HCV‑RNA replication by extracellular matrix. International Journal of Molecular Medicine.
Crossref
Crossref
Abdul Waheed Khan, Sadia Nawab, Zeeshan Nasim, Abdul Haleem Khan, Syed Ishfaq Ahmad, Fazli Zahir & Israr Ud Din. (2017) Pattern of hepatitis C virus genotypes and subtypes circulating in war-stricken Khyber Pakhtunkhwa, Pakistan: Review of published literature. Asian Pacific Journal of Tropical Medicine 10:11, pages 1037-1042.
Crossref
Crossref
Simin Xu, Brian Doehle, Sonal Rajyaguru, Bin Han, Ona Barauskas, Joy Feng, Jason Perry, Hadas Dvory-Sobol, Evguenia S Svarovskaia, Michael D Miller & Hongmei Mo. (2016)
In vitro
Selection of Resistance to Sofosbuvir in HCV Replicons of Genotype-1 to -6
. Antiviral Therapy 22:7, pages 587-597.
Crossref
Crossref
Madhumita Premkumar, Gagandeep S. Grover & Radha K. Dhiman. (2017) Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?. Journal of Clinical and Experimental Hepatology 7:3, pages 253-261.
Crossref
Crossref
Allan Peres-da-Silva, Carlos Eduardo Brandão-Mello & Elisabeth Lampe. (2016) Prevalence of Sofosbuvir Resistance-Associated Variants in Brazilian and Worldwide NS5B Sequences of Genotype-1 HCV. Antiviral Therapy 22:5, pages 447-451.
Crossref
Crossref
Rakesh Aggarwal, Qiushi Chen, Amit Goel, Nicole Seguy, Razia Pendse, Turgay Ayer & Jagpreet Chhatwal. (2017) Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. PLOS ONE 12:5, pages e0176503.
Crossref
Crossref
Cintia W. Rivero, Eliana C. De Benedetti, Fernando López Gallego, Benevides C. Pessela, José M. Guisán & Jorge A. Trelles. (2017) Biosynthesis of an antiviral compound using a stabilized phosphopentomutase by multipoint covalent immobilization. Journal of Biotechnology 249, pages 34-41.
Crossref
Crossref
R. Alonso, F. Pérez-García, D. Ampuero, E. Reigadas & E. Bouza. (2017) New direct-acting antivirals for patients with chronic HCV infection: can we monitor treatment using an HCV core antigen assay?. Diagnostic Microbiology and Infectious Disease 87:3, pages 243-246.
Crossref
Crossref
Yanzhao Chen, Baihai Jiao, Min Yao, Xuezhen Shi, Zhebin Zheng, Shilin Li & Limin Chen. (2017) ISG12a inhibits HCV replication and potentiates the anti-HCV activity of IFN-α through activation of the Jak/STAT signaling pathway independent of autophagy and apoptosis. Virus Research 227, pages 231-239.
Crossref
Crossref
Fang-Pey Chen, Ching-Mao Chang, Ta-Peng Wu, Jen-Lin Yang, Yen-Ying Kung, Yi-Hsiang Huang, Chien-Wei Su, Keng-Hsin Lan, Shu-Chiung Chiang & Shinn-Jang Hwang. (2017) Clinical efficacy of Rong-Yang-Jyh-Gan-Tang on patients with chronic hepatitis C: A double-blinded randomized placebo-controlled crossover study. Journal of Ethnopharmacology 196, pages 1-8.
Crossref
Crossref
Nannan Zhou, Zhou Han, Sandra Hartman-Neumann, Brenda DeGray, Joseph Ueland, Vincent Vellucci, Dennis Hernandez & Fiona McPhee. (2016) Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. Journal of Antimicrobial Chemotherapy 71:12, pages 3495-3505.
Crossref
Crossref
S. M. Goring, P. Gustafson, Y. Liu, S. Saab, S. K. Cline & R. W. Platt. (2016) Disconnected by design: analytic approach in treatment networks having no common comparator. Research Synthesis Methods 7:4, pages 420-432.
Crossref
Crossref
M L Zubkin, V I Chervinko, Yu V Ovchinnikov, E V Kryukov & O N Kotenko. (2016) Chronic HCV infection: An internist’s opinion (Part 2). Terapevticheskii arkhiv 88:11, pages 138-148.
Crossref
Crossref
J. Shen, M. Serby, B. Surber, A. J. Lee, J. Ma, P. Badri, R. Menon, O. Kavetskaia, S. M. de Morais, J. Sydor & V. Fischer. (2016) Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans. Drug Metabolism and Disposition 44:8, pages 1148-1157.
Crossref
Crossref
Kattareeya Kumthip & Niwat Maneekarn. (2015) The role of HCV proteins on treatment outcomes. Virology Journal 12:1.
Crossref
Crossref
Wenzhong Yan, Jie Qing, Hanbing Mei, Junxiu Nong, Jin Huang, Jin Zhu, Hualiang Jiang, Lei Liu, Linqi Zhang & Jian Li. (2015) Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition. Bioorganic & Medicinal Chemistry Letters 25:24, pages 5682-5686.
Crossref
Crossref
Tomomi Furihata, Zhongguo Fu, Yuki Suzuki, Shogo Matsumoto, Hanae Morio, Akihito Tsubota, Sayaka Matsumoto & Kan Chiba. (2015) Differential inhibition features of direct-acting anti-hepatitis C virus agents against human organic anion transporting polypeptide 2B1. International Journal of Antimicrobial Agents 46:4, pages 381-388.
Crossref
Crossref
Daniel Grint, Lars Peters, Juergen K. Rockstroh, Aza Rakmanova, Tatiana Trofimova, Karine Lacombe, Igor Karpov, Massimo Galli, Pere Domingo, Ole Kirk, Jens D. Lundgren & Amanda Mocroft. (2015) Liver-related death among HIV/hepatitis C virus-co-infected individuals. AIDS 29:10, pages 1205-1215.
Crossref
Crossref
Longhu Zhou, Hong-wang Zhang, Sijia Tao, Leda Bassit, Tony Whitaker, Tamara R. McBrayer, Maryam Ehteshami, Sheida Amiralaei, Ugo Pradere, Jong Hyun Cho, Franck Amblard, Drew Bobeck, Mervi Detorio, Steven J. Coats & Raymond F. Schinazi. (2015)
β-
d
-2′-
C
-Methyl-2,6-diaminopurine Ribonucleoside Phosphoramidates are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5′-Triphosphate Forms
. Journal of Medicinal Chemistry 58:8, pages 3445-3458.
Crossref
Crossref
A. Peres-da-Silva, A. J. de Almeida & E. Lampe. (2014) NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus. Journal of Antimicrobial Chemotherapy 70:3, pages 726-730.
Crossref
Crossref
Simon Giroux, Darius Bilimoria, Caroline Cadilhac, Kevin M. Cottrell, Francois Denis, Evelyne Dietrich, Nigel Ewing, James A. Henderson, Lucille L?Heureux, Nagraj Mani, Mark Morris, Olivier Nicolas, T. Jagadeeswar Reddy, Subajini Selliah, Rebecca S. Shawgo, Jinwang Xu, Nathalie Chauret, Francoise Berlioz-Seux, Laval C. Chan, Sanjoy K. Das, Anne-Laure Grillot, Youssef L. Bennani & John P. Maxwell. (2015) Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-Symmetric inhibitors with diyne and biphenyl linkers. Bioorganic & Medicinal Chemistry Letters 25:4, pages 936-939.
Crossref
Crossref
Márta Marschalkó, Katinka Pónyai & Sarolta Kárpáti. (2015) Sexually transmitted coinfections. HIV coinfections. Orvosi Hetilap 156:1, pages 4-9.
Crossref
Crossref
David Bonsall, M. Azim Ansari, Camilla Ip, Amy Trebes, Anthony Brown, Paul Klenerman, David Buck, Paolo Piazza, Eleanor Barnes & Rory Bowden. (2015) ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. F1000Research 4, pages 1062.
Crossref
Crossref
Mireille Mehawej, Lionel Rostaing, Laurent Alric, Arnaud Del Bello, Jacques Izopet & Nassim Kamar. (2015) Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. Journal of Transplantation 2015, pages 1-5.
Crossref
Crossref
Gyongyi Szabo, Banishree Saha & Terence N. Bukong. 2015. Biological Basis of Alcohol-Induced Cancer. Biological Basis of Alcohol-Induced Cancer
197
216
.
Evguenia S. Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, Christy Hebner, Viktoria Gontcharova, Ross Martin, Wen Ouyang, Bin Han, Simin Xu, Karin Ku, Sophia Chiu, Edward Gane, Ira M. Jacobson, David R. Nelson, Eric Lawitz, David L. Wyles, Neby Bekele, Diana Brainard, William T. Symonds, John G. McHutchison, Michael D. Miller & Hongmei Mo. (2014) Infrequent Development of Resistance in Genotype 1–6 Hepatitis C
Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical
Trials. Clinical Infectious Diseases 59:12, pages 1666-1674.
Crossref
Crossref
Simone Vasilij Benatti, Quinzan Giampaolo, Bigoni Sara, Rizzi Marco & Ripamonti Diego. (2014) Pulmonary complications associated with pegylated interferon and ribavirin in HIV/hepatitis C virus coinfected patients. AIDS 28:17, pages 2633-2635.
Crossref
Crossref
Raewyn M. Poole. (2014) Daclatasvir?+?Asunaprevir: First Global Approval. Drugs 74:13, pages 1559-1571.
Crossref
Crossref
Eric G. Meissner, David Wu, Anu Osinusi, Dimitra Bon, Kimmo Virtaneva, Dan Sturdevant, Steve Porcella, Honghui Wang, Eva Herrmann, John McHutchison, Anthony F. Suffredini, Michael Polis, Stephen Hewitt, Ludmila Prokunina-Olsson, Henry Masur, Anthony S. Fauci & Shyamasundaran Kottilil. (2014) Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. Journal of Clinical Investigation 124:8, pages 3352-3363.
Crossref
Crossref
Tomomi Furihata, Shogo Matsumoto, Zhongguo Fu, Akihito Tsubota, Yuchen Sun, Sayaka Matsumoto, Kaoru Kobayashi & Kan Chiba. (2014) Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides. Antimicrobial Agents and Chemotherapy 58:8, pages 4555-4564.
Crossref
Crossref
Eric G. Meissner, Dimitra Bon, Ludmila Prokunina-Olsson, Wei Tang, Henry Masur, Thomas R. O'Brien, Eva Herrmann, Shyamasundaran Kottilil & Anuoluwapo Osinusi. (2014) IFNL4-ΔG Genotype Is Associated With Slower Viral Clearance in Hepatitis C, Genotype-1 Patients Treated With Sofosbuvir and Ribavirin. The Journal of Infectious Diseases 209:11, pages 1700-1704.
Crossref
Crossref
Bradley Vince, John M. Hill, Eric J. Lawitz, William O’Riordan, Lynn R. Webster, Daniel M. Gruener, Ricky S. Mofsen, Abel Murillo, Eileen Donovan, Jie Chen, Joseph F. McCarville, John Z. Sullivan-Bólyai, Douglas Mayers & Xiao-Jian Zhou. (2014) A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. Journal of Hepatology 60:5, pages 920-927.
Crossref
Crossref
Makonen Belema, Van N. Nguyen, Carol Bachand, Dan H. Deon, Jason T. Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Jeffrey L. Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, Juliang Zhu, Henry S. Wong, David R. Langley, Stephen P. Adams, Glenn H. Cantor, Anjaneya Chimalakonda, Aberra Fura, Benjamin M. Johnson, Jay O. Knipe, Dawn D. Parker, Kenneth S. Santone, Robert A. Fridell, Julie A. Lemm, Donald R. O’BoyleIIII, Richard J. Colonno, Min Gao, Nicholas A. Meanwell & Lawrence G. Hamann. (2014) Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir. Journal of Medicinal Chemistry 57:5, pages 2013-2032.
Crossref
Crossref
Makonen Belema, Omar D. Lopez, John A. Bender, Jeffrey L. Romine, Denis R. St. Laurent, David R. Langley, Julie A. Lemm, Donald R. O’BoyleIIII, Jin-Hua Sun, Chunfu Wang, Robert A. Fridell & Nicholas A. Meanwell. (2014) Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors. Journal of Medicinal Chemistry 57:5, pages 1643-1672.
Crossref
Crossref
Makonen Belema, Van N. Nguyen, Jeffrey L. Romine, Denis R. St. Laurent, Omar D. Lopez, Jason T. Goodrich, Peter T. Nower, Donald R. O’BoyleIIII, Julie A. Lemm, Robert A. Fridell, Min Gao, Hua Fang, Rudolph G. Krause, Ying-Kai Wang, A. Jayne Oliver, Andrew C. Good, Jay O. Knipe, Nicholas A. Meanwell & Lawrence B. Snyder. (2014) Hepatitis C Virus NS5A Replication Complex Inhibitors. Part 6: Discovery of a Novel and Highly Potent Biarylimidazole Chemotype with Inhibitory Activity Toward Genotypes 1a and 1b Replicons. Journal of Medicinal Chemistry 57:5, pages 1995-2012.
Crossref
Crossref
David A. DeGoey, John T. Randolph, Dachun Liu, John Pratt, Charles Hutchins, Pamela Donner, A. Chris Krueger, Mark Matulenko, Sachin Patel, Christopher E. Motter, Lissa Nelson, Ryan Keddy, Michael Tufano, Daniel D. Caspi, Preethi Krishnan, Neeta Mistry, Gennadiy Koev, Thomas J. Reisch, Rubina Mondal, Tami Pilot-Matias, Yi Gao, David W. A. Beno, Clarence J. Maring, Akhter Molla, Emily Dumas, Andrew Campbell, Laura Williams, Christine Collins, Rolf Wagner & Warren M. Kati. (2014) Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A. Journal of Medicinal Chemistry 57:5, pages 2047-2057.
Crossref
Crossref
Eric Lawitz, Fred F Poordad, Phillip S Pang, Robert H Hyland, Xiao Ding, Hongmei Mo, William T Symonds, John G McHutchison & Fernando E Membreno. (2014) Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. The Lancet 383:9916, pages 515-523.
Crossref
Crossref
Maria Victoria Preciado, Pamela Valva, Alejandro Escobar-Gutierrez, Paula Rahal, Karina Ruiz-Tovar, Lilian Yamasaki, Carlos Vazquez-Chacon, Armando Martinez-Guarneros, Juan Carlos Carpio-Pedroza, Salvador Fonseca-Coronado & Mayra Cruz-Rivera. (2014) Hepatitis C virus molecular evolution: Transmission, disease progression and antiviral therapy. World Journal of Gastroenterology 20:43, pages 15992.
Crossref
Crossref
Louise Nygaard Clausen. (2014) Hepatitis C virus infection in the human immunodeficiency virus infected patient. World Journal of Gastroenterology 20:34, pages 12132.
Crossref
Crossref
Abdallah A. Yassin, Ahmed M. Elwaseef, Magdy M. Elnashar, Johannes Oldenburg, G?nter Mayer, Bernd P?tzsch & Jens M?ller. (2014) Protamine-adsorbed magnetic nanoparticles for efficient isolation and concentration of hepatitis-C virus from human plasma samples. Chem. Commun. 50:5, pages 590-592.
Crossref
Crossref
Adeyemi O AdedejiStefan G Sarafianos. (2013) Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection. Future Medicinal Chemistry 5:18, pages 2119-2122.
Crossref
Crossref
Ryan C. Schoenfeld, David L. Bourdet, Ken A. Brameld, Elbert Chin, Javier de Vicente, Amy Fung, Seth F. Harris, Eun K. Lee, Sophie Le Pogam, Vincent Leveque, Jim Li, Alfred S.-T. Lui, Isabel Najera, Sonal Rajyaguru, Michael Sangi, Sandra Steiner, Francisco X. Talamas, Joshua P. Taygerly & Junping Zhao. (2013) Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B. Journal of Medicinal Chemistry 56:20, pages 8163-8182.
Crossref
Crossref
Gaby Sroczynski & Uwe Siebert. (2013) Cost-effectiveness of direct-acting antivirals for chronic hepatitis C. Nature Reviews Gastroenterology & Hepatology 10:10, pages 572-574.
Crossref
Crossref